Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study.
Sensebé L, Giraudeau B, Bardiaux L, Deconinck E, Schmidt A, Bidet ML, Leniger C, Hardy E, Babault C, Senecal D. Sensebé L, et al. Among authors: leniger c. Blood. 2005 Jan 15;105(2):862-4. doi: 10.1182/blood-2004-05-1841. Epub 2004 Sep 14. Blood. 2005. PMID: 15367427 Free article. Clinical Trial.
Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.
Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, Le Niger C, Robin C, Ladaique P, Lapusan S, Deconinck E, Rolland C, Foote AM, François A, Jacquot C, Tardivel R, Tiberghien P, Bosson JL; Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group. Garban F, et al. JAMA Oncol. 2018 Apr 1;4(4):468-475. doi: 10.1001/jamaoncol.2017.5123. JAMA Oncol. 2018. PMID: 29392283 Free PMC article. Clinical Trial.
[Suitability of red blood cell transfusion: a multicenter study].
Gouëzec H, Berger E, Bergoin-Costello V, Betbèze V, Bourcier V, Damais A, Drouet N, Ducroz S, Fialon P, Hervé I, Huchet C, Lassale B, Léo S, Lovi V, Le Niger C, Moron S, Renom P, Delaunay C, Turmel V; Groupe des Hémobiologistes et Correspondants d'Hémovigilance. Gouëzec H, et al. Transfus Clin Biol. 2010 Dec;17(5-6):318-30. doi: 10.1016/j.tracli.2010.09.154. Epub 2010 Nov 4. Transfus Clin Biol. 2010. PMID: 21055992 French.
[Analysis of causes of destruction of labile blood products in health institutions: A multicentric study].
Damais-Cepitelli A, Leo-Kodeli S, Lovi V, Gouëzec H, Lassale B, Augey L, Berger E, Betbèze V, Bourcier V, Daurat G, Ducroz S, Huchet C, Le Niger C, Pujol S, Puntous M; pour le groupe des hémobiologistes et correspondants d’hémovigilance (GHCOH). Damais-Cepitelli A, et al. Transfus Clin Biol. 2018 Nov;25(4):242-248. doi: 10.1016/j.tracli.2018.07.009. Epub 2018 Aug 3. Transfus Clin Biol. 2018. PMID: 30145111 French.
[Is the research of posttransfusional alloantibodies still relevant?].
Le Niger C, André C, Bourcier V, Augey L, Bazin A, Berger E, Betbeze V, Damais-Cepitelli A, Daurat G, De Meyer E, Ducroz S, Gouezec H, Huchet C, Lassale B, Leo-Kodeli S, Lovi V, Puntous M, Pujol S, Renom P, Rieux C. Le Niger C, et al. Transfus Clin Biol. 2018 Feb;25(1):8-13. doi: 10.1016/j.tracli.2017.11.003. Epub 2017 Dec 19. Transfus Clin Biol. 2018. PMID: 29273503 French.
31 results